HBSP (USA)
-
Cómo China cambió su agenda global de adquisiciones
Williamson, Peter J.; Raman, Anand P.Article HBS-R1104KStrategyel progreso económico de China ha sido tan deslumbrante que la gente a menudo se olvidan de que China, Inc. ha visto su cuota de fracasos también. Basta con mirar a las primeras adquisiciones transfronterizas que las empresas chinas hicieron. Muchas de estas ofertas, incluyendo la adquisición de alto perfil de TCL de Thomson de Francia, adquisición de Ssangyong Motor Company de Corea del Sur de SAIC, y la compra de Murray de América del largo del...Starting at €8.20
-
PerkinElmer - Developing Products in China for China
Sato, Vicki L.; Jaeker, Christoph; Reda, KareemCase HBS-612032-EService and Operations ManagementTo maximize their effectiveness, color cases should be printed in color. Sym-Bio, an entrepreneurial Chinese diagnostic company with a product line in infectious disease testing, has agreed to be acquired by PerkinElmer, an international corporation with businesses in neonatal testing, life science services, and environmental health. Sym-Bio wants to accelerate its growth and competitive position in China through this strategic move, and PerkinEl...Starting at €8.20
-
How China Reset Its Global Acquisition Agenda
Williamson, Peter J.; Raman, Anand P.Article HBS-R1104K-EChina's economic progress has been so dazzling that people often forget that China, Inc. has seen its share of failures too. Just look at the first cross-border acquisitions that Chinese companies made. Many of those high-profile deals-including TCL's acquisition of France's Thomson, SAIC's takeover of South Korea's Ssangyong Motor Company, and the D'Long Group's purchase of America's Murray, Inc.-ended badly. But for the Chinese, failure is not ...Starting at €8.20
-
China Novartis Institute for Biomedical Research: Building a sustainable, globally integrated research enterprise
Sato, Vicki L.; Jaeker, Christoph; Solanki, Pooja MehtaCase HBS-612048-ETo maximize their effectiveness, color cases should be printed in color. As the head of the Novartis Institute for Biomedical Research in China, En Li was shepherding a $1 billion R&D investment in China. So far he had been able to attract a large number of Chinese-born but US-trained scientists to play a critical role in establishing the site. How sustainable was this strategy, and what were the key things he had to do right to establish a globa...Starting at €8.20